Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Invest Ophthalmol Vis Sci ; 60(4): 954-964, 2019 03 01.
Article in English | MEDLINE | ID: mdl-30882851

ABSTRACT

Purpose: To use our intra-arterial chemotherapy (IAC) rabbit model to assess the impact of IAC procedure, drug, dose, and choice of technique on ocular structure and function, to study the nature and etiology of IAC toxicity, and to compare to observations in patients. Methods: Rabbits received IAC melphalan (0.4-0.8 mg/kg), carboplatin (25-50 mg), or saline, either by direct ophthalmic artery cannulation, or with a technique emulating nonocclusion. Ocular structure/function were assessed with examination, electroretinography (ERG), fundus photography, fluorescein angiography, optical coherence tomography (OCT), and OCT angiography, prior to and 5 to 6 weeks after IAC. Blood counts were obtained weekly. We reviewed our last 50 IAC treatments in patients for evidence of ocular or systemic complications. Results: No toxicity was seen in the saline control group. With standard (0.4 mg/kg) melphalan, no vascular/microvascular abnormalities were seen with either technique. However, severe microvascular pruning and arteriolar occlusions were seen occasionally at 0.8 mg/kg doses. ERG reductions were dose-dependent. Histology showed melphalan dose-dependent degeneration in all retinal layers, restricted geographically to areas of greatest vascular density. Carboplatin caused massive edema of ocular/periocular structures. IAC patients experienced occasional periocular swelling/rash, and only rarely experienced retinopathy or vascular events/hemorrhage in eyes treated multiple times with triple (melphalan/carboplatin/topotecan) therapy. Transient neutropenia occurred after 46% of IAC procedures, generally after triple therapy. Conclusions: IAC toxicity appears to be related to the specific drug being used and is dose-dependent, rather than related to the IAC procedure itself or the specific technique selected. These rabbit findings are corroborated by our clinical findings in patients.


Subject(s)
Antineoplastic Agents, Alkylating/toxicity , Antineoplastic Agents/toxicity , Carboplatin/toxicity , Infusions, Intra-Arterial/methods , Melphalan/toxicity , Retinal Diseases/chemically induced , Retinal Vessels/drug effects , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents, Alkylating/administration & dosage , Carboplatin/administration & dosage , Dose-Response Relationship, Drug , Electroretinography , Female , Fluorescein Angiography , Humans , Infant , Male , Melphalan/administration & dosage , Models, Animal , Ophthalmic Artery/drug effects , Rabbits , Retina/physiopathology , Retinal Diseases/physiopathology , Retinal Neoplasms/drug therapy , Retinal Vessels/physiopathology , Retinoblastoma/drug therapy , Retrospective Studies , Tomography, Optical Coherence
2.
Invest Ophthalmol Vis Sci ; 59(1): 446-454, 2018 01 01.
Article in English | MEDLINE | ID: mdl-29368001

ABSTRACT

Purpose: Current intra-arterial chemotherapy (IAC) drug regimens for retinoblastoma have ocular and vascular toxicities. No small-animal model of IAC exists to test drug efficacy and toxicity in vivo for IAC drug discovery. The purpose of this study was to develop a small-animal model of IAC and to analyze the ocular tissue penetration, distribution, pharmacokinetics, and treatment efficacy. Methods: Following selective ophthalmic artery (OA) catheterization, melphalan (0.4 to 1.2 mg/kg) was injected. For pharmacokinetic studies, rabbits were euthanized at 0.5, 1, 2, 4, or 6 hours following intra-OA infusion. Drug levels were determined in vitreous, retina, and blood by liquid chromatography tandem mass spectrometry. To assess toxicity, angiograms, photography, fluorescein angiography, and histopathology were performed. For in situ tissue drug distribution, matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) was performed. The tumor model was created by combined subretinal/intravitreal injection of human WERI-Rb1 retinoblastoma cells; the tumor was treated in vivo with intra-arterial melphalan or saline; and induction of tumor death was measured by cleaved caspase-3 activity. Results: OA was selectively catheterized for 79 of 79 (100%) eyes in 47 of 47 (100%) rabbits, and melphalan was delivered successfully in 31 of 31 (100%) eyes, without evidence of vascular occlusion or retinal damage. For treated eyes, maximum concentration (Cmax) in the retina was 4.95 µM and area under the curve (AUC0→∞) was 5.26 µM·h. Treated eye vitreous Cmax was 2.24 µM and AUC0→∞ was 4.19 µM·h. Vitreous Cmax for the treated eye was >100-fold higher than for the untreated eye (P = 0.01), and AUC0→∞ was ∼50-fold higher (P = 0.01). Histology-directed MALDI-IMS revealed highest drug localization within the retina. Peripheral blood Cmax was 1.04 µM and AUC0→∞ was 2.07 µM·h. Combined subretinal/intravitreal injection of human retinoblastoma cells led to intra-retinal tumors and subretinal/vitreous seeds, which could be effectively killed in vivo with intra-arterial melphalan. Conclusions: This first small-animal model of IAC has excellent vitreous and retinal tissue drug penetration, achieving levels sufficient to kill human retinoblastoma cells, facilitating future IAC drug discovery.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacokinetics , Disease Models, Animal , Melphalan/pharmacokinetics , Retina/metabolism , Retinal Neoplasms/drug therapy , Retinoblastoma/drug therapy , Vitreous Body/metabolism , Animals , Antineoplastic Agents, Alkylating/toxicity , Electroretinography , Fluorescein Angiography , Infusions, Intra-Arterial , Melphalan/toxicity , Ophthalmic Artery/drug effects , Rabbits , Retinal Neoplasms/metabolism , Retinal Neoplasms/pathology , Retinoblastoma/metabolism , Retinoblastoma/pathology , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Tissue Distribution , Treatment Outcome
3.
J Am Heart Assoc ; 3(5): e000773, 2014 Oct 23.
Article in English | MEDLINE | ID: mdl-25341890

ABSTRACT

BACKGROUND: Neuregulin-1ß (NRG-1ß) is a growth factor critical for cardiac development and repair with therapeutic potential for heart failure. We previously showed that the glial growth factor 2 (GGF2) isoform of NRG-1ß improves cardiac function in rodents after myocardial infarction (MI), but its efficacy in a large animal model of cardiac injury has not been examined. We therefore sought to examine the effects of GGF2 on ventricular remodeling, cardiac function, and global transcription in post-MI swine, as well as potential mechanisms for anti-remodeling effects. METHODS AND RESULTS: MI was induced in anesthetized swine (n=23) by intracoronary balloon occlusion. At 1 week post-MI, survivors (n=13) received GGF2 treatment (intravenous, biweekly for 4 weeks; n=8) or were untreated (n=5). At 5 weeks post-MI, fractional shortening was higher (32.8% versus 25.3%, P=0.019), and left ventricular (LV) end-diastolic dimension lower (4.5 versus 5.3 cm, P=0.003) in GGF2-treated animals. Treatment altered expression of 528 genes, as measured by microarrays, including collagens, basal lamina components, and matricellular proteins. GGF2-treated pigs exhibited improvements in LV cardiomyocyte mitochondria and intercalated disk structures and showed less fibrosis, altered matrix structure, and fewer myofibroblasts (myoFbs), based on trichrome staining, electron microscopy, and immunostaining. In vitro experiments with isolated murine and rat cardiac fibroblasts demonstrate that NRG-1ß reduces myoFbs, and suppresses TGFß-induced phospho-SMAD3 as well as αSMA expression. CONCLUSIONS: These results suggest that GGF2/NRG-1ß prevents adverse remodeling after injury in part via anti-fibrotic effects in the heart.


Subject(s)
Heart Failure/drug therapy , Myocardium/pathology , Neuregulin-1/pharmacology , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Actins/metabolism , Animals , Cells, Cultured , Disease Models, Animal , Dose-Response Relationship, Drug , Fibrosis , Gene Expression Regulation/drug effects , Heart Failure/genetics , Heart Failure/metabolism , Heart Failure/pathology , Heart Failure/physiopathology , Male , Mice, Inbred C57BL , Myocardial Contraction/drug effects , Myocardium/metabolism , Myofibroblasts/drug effects , Myofibroblasts/metabolism , Myofibroblasts/pathology , Phosphorylation , Rats, Sprague-Dawley , Smad3 Protein/metabolism , Swine , Time Factors , Transcription, Genetic/drug effects , Ventricular Remodeling/genetics
4.
Dev Genes Evol ; 214(3): 144-8, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14758554

ABSTRACT

Wnt signaling molecules regulate the development of multiple organs in vertebrate embryos. We have isolated cDNA clones for frizzled10 (Fz10), which encodes a putative Wnt receptor, to further characterize the mechanisms of Wnt signaling in mouse embryos. Interestingly, Fz10 is expressed in the same regions as Wnt7a in the neural tube, limb buds, and Müllerian duct.


Subject(s)
Embryo, Mammalian/metabolism , Receptors, Cell Surface/genetics , Signal Transduction/physiology , Amino Acid Sequence , Animals , Extremities/embryology , Extremities/growth & development , Frizzled Receptors , Gene Expression Regulation, Developmental , Mice , Molecular Sequence Data , Receptors, Cell Surface/metabolism , Receptors, G-Protein-Coupled , Sequence Homology, Amino Acid
5.
J Endourol ; 17(5): 307-12, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12885356

ABSTRACT

BACKGROUND AND PURPOSE: Laparoscopic radical cystectomy with orthotopic ileal neobladder creation is a technically challenging and lengthy surgical procedure. We present our experience with a simplified technique for laparoscopic cystectomy and neobladder creation in the porcine model. MATERIALS AND METHODS: Ten female minipigs underwent a purely laparoscopic radical cystectomy with orthotopic ileal neobladder creation. Nine ureterointestinal anastomoses were performed using a simplified "dunk" technique, where the ureter was prolapsed 5 mm into the afferent limb and the periureteral tissue was secured to the bowel serosa with three superficial sutures. Six ureters were not stented, and three had indwelling stents inserted. In 11 ureters, the anastomosis was performed using a running mucosa-to-mucosa technique (three with stents, eight without stents). The Lapra-Ty suture clip (Ethicon Endosurgery, Cincinnati, OH) was used to secure the running sutures on the urethra, ureters, and neobladder. Animals were harvested at 3 to 8 weeks (mean 6.5 weeks) after surgery. Serology, static cystogram, intravenous urography, and gross and histopathologic evaluations were performed. RESULTS: Of six unstented dunked ureterointestinal anastomoses, two (33%) were widely patent, two were strictured but patent, and two were completely obstructed. In the three stented ureters implanted using the dunk technique, one (33%) was widely patent, one was strictured, and one was completely obstructed. All ureterointestinal anastomoses performed with a mucosa-to-mucosa running anastomosis, whether stented (three ureters) or not stented (eight ureters), were widely patent. Lapra-Ty clip migration into the neobladder pouch caused urethral obstruction resulting in delayed bladder perforation in two animals. CONCLUSIONS: Laparoscopic cystectomy and ileal neobladder creation is technically feasible. Attempts to simplify the ureterointestinal anastomosis require further evaluation and modification. Stent placement appears to be unnecessary in the laparoscopic ureterointestinal anastomosis. Laparoscopic creation of the ileal neobladder remains a technically challenging procedure.


Subject(s)
Cystectomy/methods , Ileum/surgery , Laparoscopy/methods , Urinary Reservoirs, Continent , Anastomosis, Surgical , Animals , Disease Models, Animal , Female , Minimally Invasive Surgical Procedures/methods , Recovery of Function , Swine, Miniature , Treatment Outcome , Urodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...